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Introduction
The thyroid gland is part of the
endocrine system and has a
widespread function that controls
multiple organ systems and
processes. The main function of
the thyroid gland is to produce
and secrete two different thyroid
hormones: triiodothyronine (T3)
and thyroxine (T4), both of which
help to meet the metabolic
demands of the entire body.
When the thyroid gland fails to
produce T3/T4 hormones
(primary gland failure) or is not
activated successfully by the
pituitary gland (by the release of
thyroid stimulating hormone
(TSH)), or hypothalamus, this
results in low levels of circulating
thyroid hormone. As low levels of
the circulating thyroid hormones
continue, an overall slowing of the
person’s metabolism occurs. This
underactive thyroid disease is
called hypothyroidism (Chiasera,
2013).
Although there are several
causes for hypothyroidism,
Hashimoto’s Thyroiditis (HT) is
the most common cause of
hypothyroidism in United States
and is thought to be associated
with genetic susceptibility and
environmental factors. HT is a
chronic autoimmune disease and
can present itself in an aggressive
form or a mild form such as silent
thyroiditis or postpartum
thyroiditis leading to an
undiagnosed hypothyroidism.
Regardless of the virulence of the
disease, HT can become serious if
left untreated (Davies, 2015).

Pathophysiological Process and Significance
HT is caused by an overt autoimmune
response causing thyroid gland
destruction. Loss of immune tolerance
(lack of regulatory T-cells) to normal
thyroid cells leads to the production of
antibodies directed against thyroid tissue,
which causes destruction of the thyroid
gland. This destruction inhibits the release
of thyroid hormones necessary for the
metabolic processes.
The disease begins with an activated
inflammatory process when an individual
is genetically (familial) and
environmentally (iodine diet, toxins, viral
infect) predisposed for HT. This
inflammatory process initiates the
accumulation of the human leukocyte
antigen (HLA) Class II antigen-presenting
cells (APC) into the thyroid gland. HLA
Class II is a set of molecules found on
antigen-presenting cells such as dendritic
cells and subclasses of macrophages. HLAs
present antigens from outside of the cell to
T-lymphocytes. This stimulates the
multiplication of T-helper cells. T-helper
cells then stimulates B-cells to produce
antibodies to the specific antigen. When
there is an accumulation of HLA Class II
molecules in the thyroid gland, this causes
damage to thyrocytes and causes the
release of thyroid-specific proteins that are
then seen on the cell surface of the encoded
APC. From here, the APC travels from the
thyroid gland to the draining lymph nodes
of the thyroid. When the encoded APC
interacts with the T-lymphocyte cells and
B-lymphocyte cells in the draining lymph
nodes, a production of thyroid
autoantibodies occur against the thyroid
antigens: thyroid peroxidase (TPO) and
thyroglobulin (Tg). Once the production of
thyroid autoantibodies (anti-Tg antibodies
and anti-thyroperoxidase antibodies)
occurs, antigen-producing B-lymphocytes,
T helper cells (CD4+), and cytotoxic T cells
(CD+8), and macrophages infiltrate and
accumulate in the thyroid gland through
the formation, clonal expansion, and
maturation of self-reactive T lymphocytes
and B-lymphocytes in the lymph tissue of
the thyroid gland. This entire process of
autoantibody, cytokine-mediated and
apoptotic mechanisms of cytotoxicity leads
to the destruction of the thyroid gland.
This thyroid gland destruction inhibits the
release of the thyroid hormones
Triiodothyronine (T3) and Thyroxine (T4).
This lack of hormone release leads to
hypothyroidism and Hashimoto’s
Thyroiditis (Davies, 2015).

Hashimoto’s thyroiditis is one of the most common
autoimmune diseases in the United States. The name
of this disease was derived from the 1912 pathology
report completed by Dr. Hakaru Hashimoto (Caturegli
et al., 2013). It is estimated that one in 300 persons in
the United States has been diagnosed with some form
of hypothyroidism and an estimated 13 million
persons have hypothyroidism, but have not been
properly diagnosed. Hypothyroidism may not be
present until later in life and affects women more than
men. Often times, hypothyroidism is ignored or
misdiagnosed due to the multiple symptoms that
appear similar to other diseases (Gaitonde, Rowley, &
Sweeney, 2012).
Due to the widespread function of the thyroid gland,
an untreated hypothyroidism can lead to multisystem
complications including; cardiovascular diseases,
pregnancy complications, and even life-threatening
conditions. An accurate diagnoses and treatment is
critical. Any form of hypothyroidism such as
Hashimoto’s Thyroiditis is a serious disease and
should be treated as such (Mendes, 2015).

Signs and Symptoms
Since the thyroid gland regulates the entire metabolism, the
thyroid gland indirectly affects every cell, tissue, and organ in
the body – from muscles, bones, and skin to the digestive
tract, heart, and brain. Since the thyroid gland is a
multisystem functioning gland, there are a wide variety of
signs and symptoms that may be present with Hashimoto’s
disease and/or any form of hypothyroidism. Regardless of
which type of hypothyroidism a person may have, the possible
signs and symptoms will be the same. Initially,
hypothyroidism may present itself in a subclinical manner
(mild and without symptoms), but as the disease progresses
the symptoms become more apparent (NIH, 2013).
Signs and symptoms that can be seen in someone with a
hypothyroid disease are: fatigue, constipation, dry skin,
increased sensitivity to cold, muscle weakness, cramps or
stiffness, coarse brittle thinning hair, brittle nails, hoarse
voice, unintentional weight gain, depression, menstrual
irregularities; heavy and excessive bleeding. Physical exam
findings that may also be seen are: bradycardia, goiter,
diastolic hypertension, cognitive impairment, delayed deep
tendon reflexes, edema, altered laboratory results: elevated
TSH, decreased Free T4, normal or sometimes decreased Total
or Free T3, hyperlipidemia, hyponatremia, and elevated
creatine kinase, Hashimoto’s specific: Elevated serum
concentrations of TPO autoantibodies (Ross, 2015).
In general, these symptoms are due to the decreased
production of thyroid hormone. Most of the symptoms are
not manifested in the early stages of the disease, but as the
disease progresses, the degree of the disease along with
clinical manifestations will worsen. When the metabolic rate
drops to a critical level, a life threatening emergency known as
“Myxedema Coma” can occur. This event is characterized by
hypothermia, hypoglycemia, severe bradycardia and altered
level of consciousness (Hampton, 2013). Proper diagnoses
and treatment is life or death when dealing with
hypothyroidism.

Nursing Implications
Since HT and hypothyroidism can present itself in a variety of
ways and level of severity, the most important factor is an
accurate recognition and diagnosis. Diagnosing should always
begin with a thorough physical exam and obtaining a complete
medical history. Taking time to interview the patient and truly
hear what is being said is crucial. In addition, focusing on one
symptom will prevent a healthcare provider from accurately
diagnosing someone with HT. The healthcare provider needs to
be well educated about hypothyroidism and its presenting
symptoms. Again, HT and/or hypothyroidism can easily be
mistaken for other medical problems due the thyroid gland being
a multisystem gland, which is why it is so important for healthcare
providers to be well educated about this disease.
When the physical exam and medical history is complete and
hypothyroidism or HT is suspected, diagnostic lab work must be
obtained to confirm the diagnosis. Lab work usually begins with a
TSH level. Normally, a TSH level above normal is indicative of
hypothyroidism. In addition, a T4 level should be obtained and
will be lower than normal with hypothyroidism. Although most
persons with HT will eventually develop hypothyroidism due to
the destruction of the thyroid gland, the TSH and T4 may present
normally since hypothyroidism has not occurred at this time. For
a definitive diagnosis of HT, a person must test positive for serum
antithyroid antibodies. This test confirms the presence of
autoantibodies that mistakenly attack the thyroid tissue. A
computerized tomography (CT) scan may also be performed to
assess the thyroid gland for size, texture, nodules, and/or
inflammation (NIH, 2013).
Treatment for HT depends upon goiter activity and/or if
hypothyroidism is present. If a person with HT does not have
hypothyroidism and/or a goiter, continued monitoring should
take place. If a person with HT has a goiter but is still free of
hypothyroidism, healthcare providers may treat the person in an
effort to decrease the size of the goiter. When a person with HT is
positive for hypothyroidism, they must be treated with synthetic
T4 (synthetic T4 stays in the body longer than synthetic T3). The
most common form of synthetic T4 that is currently being used is
Synthroid. Once Synthroid is initiated, healthcare providers must
monitor the patient’s lab work closely to prevent the counter
effect of hyperthyroidism. Usually, lab work is rechecked every 3
months after the initial start of Synthroid and/or if changes are
being made to the patient’s Synthroid dosage (NIH, 2013).
Finally, another very important nursing implications is patient
education. It is very important that a patient understands the
disease, the importance of the treatment, and most importantly,
compliance with taking medication as prescribed. Noncompliance
is not an option with HT. Patient compliance is important in
preventing extreme hypothyroidism such as Myxedema Coma.

Conclusion
In conclusion, HT is characterized by the loss of thyroid
follicular cells, hypothyroidism, and the presence of
autoantibodies against tissue-specific antigens such as thyroid
peroxidase (TPO) and thyroglobulin (Tg). The thyroid tissue is
identified as having an infiltration of T cells and B cells which are
reactive against the thyroid antigens. The lymph system of the
thyroid gland becomes involved and this leads to the death of the
thyrocytes with the end result of hypothyroidism and Hashimoto’s
Thyroiditis (Glick, Wodzinski, Fu, Levine, & Wald, 2013).
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